Adamas Pharmaceuticals Inc (OQ:ADMS)

Business Focus: Biotechnology & Medical Research

Sector:  Healthcare Industry:  Biotechnology & Medical Research
 
See Regulatory Filings on SEC
Company Contact
Address: 1900 Powell St Ste 1000
EMERYVILLE CA 94608-1839
Tel: N/A
Website: https://adamaspharma.com
IR: See website
<
Key People
David L. Mahoney
Lead Independent Chairman of the Board
Neil McFarlane
Chief Executive Officer, Director
Christopher B. Prentiss
Chief Financial Officer, Chief Accounting Officer, Principal Financial Officer and Principal Accounting Officer
Vijay Shreedhar
Chief Commercial Officer
   
Business Overview
Adamas Pharmaceuticals, Inc. is a pharmaceutical company. The Company is engaged in developing medicines to manage the daily lives of those affected by chronic neurologic disorders. It offers a platform based on an understanding of time dependent biologic effects of disease activity and drug response to achieve relief without tolerability issues. It has developed a portfolio of chrono-synchronous therapies to address chronic neurologic disorders. Its first product candidate is ADS-5102, a chrono-synchronous amantadine therapy, for the treatment of levodopa-induced dyskinesia (LID) in patients with Parkinson's disease (PD). It has completed Phase II proof-of-concept study of ADS-5102 in these patients. Its Phase III clinical program included three placebo-controlled trials: EASED, EASE LID and EASE LID 3. Its second product candidate is ADS-4101, an extended-release version of single-agent compound for the treatment of epilepsy (partial onset seizures).
Financial Overview
For the three months ended 31 March 2020, Adamas Pharmaceuticals Inc revenues increased 24% to $14.5M. Net loss decreased 44% to $16.6M. Revenues reflect an increase in demand for the Company's products and services due to favorable market conditions. Lower net loss reflects Other Research and Development. decrease of 75% to $2.4M (expense), Other General and Administrative. decrease of 7% to $23.2M (expense).
Employees: 136 as of Dec 31, 2019
Reporting Currency: U.S. Dollars
Enterprise value: $88.07M as of Mar 31, 2020
Annual revenue (TTM): $57.45M as of Mar 31, 2020
EBITDA (TTM): -$77.61M as of Mar 31, 2020
Net annual income (TTM): -$92.18M as of Mar 31, 2020
Free cash flow (TTM): -$77.19M as of Mar 31, 2020
Net Debt Last Fiscal Year: $14.02M as of Mar 31, 2020
Shares outstanding: 28,158,205 as of Apr 8, 2020
TTM: Trailing Twelve Months
EBITDA: Earnings Before Interest, Taxes, Depreciation, & Amortization